The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The benefit of rituximab (RTX) for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has been shown in previous clinical trials. However, predictors of RTX efficacy have not been clarified. We investigated whether B‐cell responsiveness to RTX is related to therapeutic effect. Ten SSc‐ILD patients treated with RTX in an independent clinical trial (Japan Registry of Clinical Trials,...
Systemic sclerosis (SSc) is an autoimmune disorder characterized by vascular damage and excessive fibrosis. SSc‐associated interstitial lung disease (ILD) is a leading cause of death in SSc. Several studies have shown the efficacy of rituximab (RTX) in SSc‐ILD, but no study has examined the relation between RTX reactivity and change of serum marker levels. In this study we examined the relation between...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.